Waiting
Login processing...

Trial ends in Request Full Access Tell Your Colleague About Jove
JoVE Journal
Cancer Research

A subscription to JoVE is required to view this content.

Een GPC3-targeting bispecifieke antilichaam, GPC3-S-Fab, met krachtige cytotoxiciteit
 
Click here for the English version

Een GPC3-targeting bispecifieke antilichaam, GPC3-S-Fab, met krachtige cytotoxiciteit

Article DOI: 10.3791/57588-v 11:13 min July 12th, 2018
July 12th, 2018

Chapters

Read Article

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
Simple Hit Counter